Soft-tissue sarcoma

Last reviewed: 21 Apr 2022
Last updated: 24 Nov 2021

Summary

Definition

History and exam

Key diagnostic factors

  • mass
  • upper/lower gastrointestinal bleed
  • rash
  • purplish macular-papular lesions
  • dysfunctional uterine bleeding
  • increased abdominal girth
  • history of HIV infection
  • features of acute abdomen
  • neuropathic pain
More key diagnostic factors

Other diagnostic factors

  • weight loss
  • fatigue
  • anorexia
  • abdominal bloating, discomfort, pain
  • unilateral extremity swelling
Other diagnostic factors

Risk factors

  • genetically inherited syndromes
  • radiation
  • human herpesvirus-8 (HHV-8) infection
  • congenital disorders
  • lymphoedema
  • history of exposure to chemical carcinogens
More risk factors

Diagnostic investigations

1st investigations to order

  • CT scan of primary tumour
  • MRI of primary tumour
  • CT scan chest
  • HIV test
More 1st investigations to order

Investigations to consider

  • ultrasound of primary tumour
  • chest x-ray
  • positron emission tomography (PET) scan
  • endoscopy
  • biopsy for histology
  • full blood count (FBC)
  • urea
  • creatinine
  • liver function tests (LFTs)
  • echocardiogram or multi-gated acquisition (MUGA) scan
  • gene rearrangement testing
More investigations to consider

Treatment algorithm

ACUTE

extremity: stage I

extremity: stage II-III, resectable

extremity: stage II-III, unresectable

extremity: stage IV, single organ plus limited tumour bulk or regional nodes

extremity: stage IV, disseminated metastases

retroperitoneal/intra-abdominal: resectable

retroperitoneal/intra-abdominal: unresectable or stage IV

gastrointestinal stromal tumours: localised or potentially resectable

gastrointestinal stromal tumours: unresectable or metastatic

ONGOING

recurrence

Contributors

Authors

James S. Hu, MD, FACP

Associate Professor of Clinical Medicine

USC Norris Comprehensive Cancer Center

Los Angeles

CA

Disclosures

JSH declares that he has no competing interests.

Swati Sikaria, MD

Fellow

USC Norris Comprehensive Cancer Center

Los Angeles

CA

Disclosures

SS declares that she has no competing interests.

Sant P. Chawla, MD, FRACP

Director

Sarcoma Oncology Center

Santa Monica

CA

Disclosures

SPC declares that he has no competing interests.

Acknowledgements

Dr James S. Hu, Dr Swati Sikaria, and Dr Sant P. Chawla would like to gratefully acknowledge Dr Jonathan C. Trent, Dr Saira Hassan, and Dr David Thomas, previous contributors to this topic.

Disclosures

JCT and SH each declare that they have no competing interests. DT has received research support from Pfizer, Amgen, and Novartis.

Peer reviewers

Alfio Ferlito, MD, DLO, DPath, FRCSEd

Director

Department of Surgical Sciences

Professor and Chairman

ENT Clinic

University of Udine

Udine

Italy

Disclosures

AF declares that he has no competing interests.

Adrienne Flanagan, MB BCh FRCPath PhD

Professor of Musculoskeletal Pathology

Institute of Orthopaedics and Musculoskeletal Science

University College London

Stanmore

UK

Disclosures

AF declares that she has no competing interests.

Robert Maki, MB, PhD

Medical Oncologist

Memorial Sloan-Kettering Cancer Center

New York

NY

Disclosures

RM declares that he has no competing interests.

  • Differentials

    • Lipoma
    • Gastrointestinal ulcer
    • Lymphoma
    More Differentials
  • Guidelines

    • Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up
    • Trabectedin for the treatment of advanced soft tissue sarcoma
    More Guidelines
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer